DUBLIN--(BUSINESS WIRE)--Presbia PLC (NASDAQ: LENS), an ophthalmic device company that has developed and is currently marketing the Presbia Flexivue Microlens™, a proprietary optical lens implant for treating presbyopia, announced today the appointment of John Strobel as Vice President of Sales. Mr. Strobel will be responsible for Presbia’s international sales expansion of the Presbia Flexivue Microlens™.
“John’s extensive experience in the ophthalmology industry as well as his demonstrated track record of expanding international sales will be extremely valuable as we broaden our commercialization across the globe,” said Todd Cooper, President and CEO of Presbia. “John’s proven leadership abilities to attract, retain, and manage an international sales team will accelerate the execution of our international growth strategy, and increase the world-wide availability of this revolutionary treatment option to presbyopia patients.”
Mr. Strobel has extensive background in international sales and ophthalmology. He most recently served as Vice President of Sales and Marketing of Western Enterprises. Prior to that, Mr. Strobel served as Vice President of Sales and Marketing for Volk Optical, a diagnostic and surgical device manufacturer in the ophthalmology and optical markets. Over his 12 years at the firm, he built a global selling team in over 100 countries and drove 12 consecutive years of record revenues and increase in net profit as well as opening new offices and managing teams in India, China, Latin America, Europe, Middle East/Africa, and Australia. Earlier in his career, Mr. Strobel served in sales management roles at Hu-Friedy, a $100 million dental manufacturer and Depuy/Motech Spinal Systems.
Mr. Strobel earned a Bachelor of Science in Biomedical Engineering from Tulane University and a Master of Business Administration in International Management from Thunderbird School of Global Management.
Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.